Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Progestin in Fertility-Sparing Treatment for Endometrial Cancer
NCT07900256Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2026
- Primary completion
- Apr 2033
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in endometrial cancer (EC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Complete Response Rate at 6 months and Duration of Complete Response at 36 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07900256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900256.